Pulse Biosciences, Inc (NASDAQ:PLSE) Given Average Rating of “Moderate Buy” by Brokerages

Posted by on Aug 17th, 2026

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report) have received an average recommendation of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $45.25.

PLSE has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Needham & Company LLC started coverage on shares of Pulse Biosciences in a report on Monday. They issued a “buy” rating and a $58.00 price objective for the company. Canaccord Genuity Group raised their price target on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Mizuho set a $45.00 target price on Pulse Biosciences in a report on Monday, August 10th. Finally, Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th.

Read Our Latest Stock Report on PLSE

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PLSE. BNP Paribas Financial Markets boosted its position in shares of Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after buying an additional 680 shares during the period. Osterweis Capital Management Inc. bought a new position in shares of Pulse Biosciences in the second quarter valued at approximately $28,000. Tower Research Capital LLC TRC boosted its holdings in Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after buying an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after buying an additional 619 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Pulse Biosciences in the 2nd quarter valued at about $158,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Stock Performance

PLSE stock opened at $44.54 on Monday. The firm has a 50-day simple moving average of $30.86 and a two-hundred day simple moving average of $24.74. Pulse Biosciences has a one year low of $12.56 and a one year high of $46.97. The firm has a market cap of $3.08 billion, a price-to-earnings ratio of -37.75 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The company had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.53 million. As a group, equities analysts predict that Pulse Biosciences will post -1.29 earnings per share for the current fiscal year.

Pulse Biosciences Company Profile

(Get Free Report)

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

Featured Stories

Analyst Recommendations for Pulse Biosciences (NASDAQ:PLSE)

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.